Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SPY072 in Moderately to Severely Active Rheumatologic Disease
2025-521791-63-00Phase 2Authorised
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of SPY072 in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) (6 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoints: Change from baseline in DAS28-CRP at Week 12 (RA substudy), Change in ASDAS from baseline to Week 16 (axSpA substudy) and 1 more. Planned start Nov 2025; status: authorised.
02
Drugs
SPY072
03
Conditions
rheumatoid arthritis (RA)axial spondyloarthritis (axSpA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-521791-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521791-63-00.